2,354 material Form 8-K filings that 2,004 companies we cover made with the SEC in November 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 1,081 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Oppenheimer Holdings subsidiary Viner Finance entered into a lease on November 5, 2026, for about 221,339 rentable square feet at 32 Old Slip in Lower Manhattan, to serve as the firm's principal New York City offices. Fixed annual rent is approximately $13.3 million for the first five years after rent commencement, rising in later periods, and the company expects significant additional capital spending for furniture, equipment and technology tied to the relocation.
Lease covers about 221,339 rentable square feet with an initial term of approximately 15.5 years.
Rent commencement is the later of six months after final delivery of the Premises and July 1, 2028; fixed rent is about $13.3 million a year for the first five years, $14.4 million for the next five, and $15.5 million thereafter.
Viner has an option to terminate at the tenth anniversary of rent commencement for a termination fee of a maximum aggregate of approximately $24 million.
Oppenheimer's press release says phased move-in is targeted to begin in the first quarter of 2028.
Exascale Labs countersigned a $9.04 million firm purchase order for 16 Intel BHS 10U GPU servers with NVIDIA HGX B300 GPUs from Compal Electronics. The filing also describes a framework that would let the company buy up to 128 servers in total, but it places no minimum purchase obligation on the company, and the second order has not been placed. The filing does not describe financial results, and it is not clear how the servers will be funded or used.
Purchase covers 16 servers at $565,000 each, for an aggregate price of $9,040,000 excluding taxes
Down payment of $1,808,000 (20%) due within five business days of Compal's written order confirmation; remaining $7,232,000 (80%) due before shipment
Framework allows purchases of up to 128 servers through March 31, 2027, with no minimum commitment; no order has been placed under the second framework agreement
Company agreed to a storage arrangement and a three-year warranty from Compal; Compal and the company are described as unaffiliated
Aptevo Therapeutics reported on November 9, 2026 that it presented new preclinical data from its next-generation multispecific platform at the SITC 2026 Annual Meeting on November 7, 2026. The lab results cover APVO451, APVO452 and APVO711, which the company says showed tumor-cell killing and immune activation under conditions that suppress immune responses. The filing contains no financial results, and the data are early-stage, so the update does not change reported financials.
Presentation made on November 7, 2026 at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting.
APVO451 and APVO452 showed tumor-cell killing and T-cell activation under immunosuppressive conditions in preclinical studies.
APVO711 combined CD40 activation with PD-L1 checkpoint blockade in preclinical findings.
APVO451 and APVO452 are expected to advance into IND-enabling studies in 2027.
Canton Strategic Holdings announced that the first trades of its issuer-sponsored tokenized common stock occurred on November 4, 2026, on TSV LLC's venue on the Canton Network, under the SEC's September 17 Innovation Exemption. The filing contains no financial results, guidance, or financial figures; it describes a new trading and recordkeeping arrangement for the company's shares.
First tokenized CNTN trades executed November 4, 2026 on TSV LLC, with Five North as seller, DRW Cumberland as buyer and Flowdesk as liquidity provider.
Fairmint TA LLC, the company's SEC-registered transfer agent, records the tokenized shares; holders must be verified before holding or trading.
Tokenized shares carry the same rights as CNTN stock traded on Nasdaq, according to the company, and trading is available 24/7 on the venue, subject to stated limits.
First Breach announced a supplier agreement giving it the ability to purchase up to 20 million primers per month, two additional ammunition inspection units, and a separate raw material supply agreement. The company says these steps support plans to scale ammunition production toward up to 20 million rounds per month and move toward 24-hour operations.
Primer agreement allows purchases of up to 20 million primers per month from a strategic supplier
Two additional ammunition inspection units added, supplementing equipment acquired earlier this year at the Hagerstown, Maryland facility
Separate raw material supply agreement announced; no financial terms, dollar values or contract durations were disclosed
Filing is a Regulation FD disclosure furnishing the November 3, 2026 press release; no financial results were reported
On November 5, 2026, the sponsor 21Shares US LLC gave notice to House of Doge Inc. terminating, effective immediately, a Support Services Agreement covering research, data, operational support and marketing services for the trust. The sponsor said it elected to terminate the agreement under its terms. The filing does not state a reason or name a replacement provider, and the terms of the services transition are not described.
Notice given November 5, 2026; termination effective immediately
Agreement is between the sponsor, 21Shares AG and House of Doge Inc.
Services covered include research, data, operational support and marketing for the trust
Filing states the sponsor elected to terminate under the agreement's terms
Nkarta, Inc. announced it will host a webcast on Monday, November 9, 2026, at 8:00 a.m. Eastern Time to review initial clinical data for its NKX019 cell therapy candidate in myositis and systemic sclerosis, presented at the American College of Rheumatology Convergence 2026. The filing contains no financial results, and the company did not disclose the clinical data itself in this document, so shareholders will learn the results at the webcast.
Webcast set for Monday, November 9, 2026, at 8:00 a.m. ET
Initial data covers NKX019 in myositis and systemic sclerosis under the Ntrust program
Data to be presented at ACR Convergence 2026 in Orlando; replay to be archived on Nkarta's investor website
Parabilis Medicines entered into a Third Amendment to its lease for its Cambridge, Massachusetts headquarters, adding 33,525 square feet of space at the neighboring 20 Acorn Park Drive and extending the lease term through December 31, 2037. The filing describes this as a lease change, and it does not state any financial effect on the company's results.
Amendment dated October 30, 2026, with LS 400/500 CDP, LLC, amends the 2019 headquarters lease.
Expansion of 33,525 square feet on the first and sixth floors of 20 Acorn Park Drive begins January 1, 2028, with rent commencing January 1, 2029.
Lease extension term runs from March 1, 2031 to December 31, 2037, with eight months of base rent abatement subject to conditions.
The company gets an option to extend the lease for two additional five-year periods.
Kairos Pharma announced it was named a winner of the 2026 Biotech Breakthrough Awards in the Cancer Immunology Solution of the Year category for its ENV-105 (carotuximab) work in metastatic prostate cancer and non-small cell lung cancer. The filing reports no financial results, guidance, or transaction, so the award itself does not change reported financial figures.
Award: Cancer Immunology Solution of the Year, 2026 Biotech Breakthrough Awards
Lead candidate ENV-105 (carotuximab) is in development for metastatic prostate cancer and non-small cell lung cancer
Press release references earlier positive interim Phase 2 efficacy data for ENV-105 with apalutamide in metastatic castration-resistant prostate cancer
Press release dated November 5, 2026, furnished as Exhibit 99.1
Immunic, Inc. disclosed that it is hosting a Progressive Multiple Sclerosis (PMS) Research and Development Day webinar on November 5, 2026, from 12:30 p.m. to 2:00 p.m. ET. The company furnished a presentation for the event as Exhibit 99.1. The filing contains no financial results, guidance, or transaction terms.
PMS R&D Day webinar held via video conference on Thursday, November 5, 2026, 12:30 p.m. to 2:00 p.m. ET
Presentation dated November 5, 2026, furnished as Exhibit 99.1 and not deemed filed under Section 18 of the Exchange Act
Forward-looking statements cite the feasibility of advancing vidofludimus calcium to a confirmatory phase 3 trial in progressive multiple sclerosis
NextTrip announced a broader U.S. rollout of JOURNYGO, its program-linked travel itinerary and booking service, following the initial beta phase. The filing gives no revenue, profit or cost figures, so shareholders have no financial impact to measure yet.
Rollout begins in November 2026 with about 60 content pieces and itineraries, adding JOURNY TV programming and distribution on Samsung TV Plus and Plex.
In the initial test, as many as 30% of viewers clicked through to JOURNYGO.
JOURNYGO content averages nearly 10 minutes of engagement per active user during beta and early use.
Aptevo Therapeutics said successive refinements to the priming-dose regimen for its lead candidate, mipletamig, substantially reduced infusion-related reactions in the ongoing RAINIER study in frontline acute myeloid leukemia. The company said the change supports its preparation for Phase 2 development, which it expects to initiate in 2027, but the filing gives no numerical measure of the reduction and states that the findings do not establish improved efficacy.
Successive priming-dose refinements substantially reduced infusion-related reactions, per the press release; no reduction percentage is disclosed.
Mipletamig data will be presented at the ASH 68th Annual Meeting, December 12-15, 2026, in New Orleans.
Aptevo expects to complete the RAINIER study by year-end 2026 and initiate Phase 2 development in 2027.
Microbot Medical announced that the Canadian Intellectual Property Office granted it a patent for an adaptor that couples a surgical tool such as a guidewire or microcatheter to a motorized robotic surgical device. The company now holds 45 issued patents and 48 patent applications worldwide, including 21 issued patents in North America. The filing contains no financial results, and it does not quantify any effect on sales or revenue.
Canadian Intellectual Property Office granted the patent, announced November 5, 2026
Company holds 45 issued patents and 48 patent applications worldwide as of November 5, 2026
21 of the issued patents are in North America
Company says the patent supports potential future market expansion and regulatory pursuits in additional markets
Genprex reported results from a translational analysis of whole-blood samples from 11 lung cancer patients treated with its lead drug candidate, REQORSA, presented as a poster at the Gerontological Society of America 2026 Annual Scientific Meeting. The company says the findings suggest a shift toward cellular repair and maintenance pathways, but the filing reports no revenue, earnings, guidance, or financing figures, so the news is exploratory and carries no reported financial impact.
Analysis used whole-blood samples from 11 lung cancer patients in two REQORSA clinical trials, taken before treatment and at 5 and 24 hours after infusion.
At 5 hours the response was dominated by innate immune pathways, which the company says is most consistent with a nonspecific reaction to the lipid nanoparticle delivery system.
At 24 hours the profile shifted toward cellular maintenance, and the poster was presented at the GSA meeting taking place November 4-7, 2026, in National Harbor, Maryland.
The filing includes forward-looking warnings and notes that the company's listing compliance on The Nasdaq Capital Market and its ability to continue as a going concern remain risk factors.
Evommune announced a pre-recorded webcast at 8:30 a.m. ET on November 5, 2026, where CEO Luis Peña and management will discuss EVO570, an oral VAV1-directed molecular glue degrader the company in-licensed from Hinova Pharmaceuticals. The filing contains no new financial results or deal terms, but it signals management's focus on the transaction and the planned rheumatoid arthritis development path.
Pre-recorded webcast available at 8:30 a.m. ET on Thursday, November 5, 2026, with an archived replay for 30 days
Exclusive license from Hinova Pharmaceuticals (SSE: 688302) grants worldwide rights to EVO570 outside Greater China
Webcast will not include a live question-and-answer session; questions can go to investor relations
EVO570 is an investigational drug candidate and has not been approved by any regulatory authority
Uranium Energy Corp (UEC) said its subsidiary has entered into definitive long-term sales agreements with two U.S. nuclear utilities covering 1.1 million pounds of uranium concentrates delivered over six years. Each delivery is priced at prevailing spot market prices, so the company stays fully unhedged to future uranium prices. The filing gives no contract value, so the financial effect on shareholders cannot be measured from this document.
Two contracts cover a total of 1,100,000 pounds of uranium concentrates (U3O8), delivered over six years.
One contract delivers 100,000 pounds per year from 2027 through 2032; the other from 2028 through 2032.
All deliveries are priced at prevailing spot market prices; the filing discloses no contract value or floor and ceiling terms.
The company cited a fiscal year 2026 average realized price of $93.13 per pound.
Citius Pharmaceuticals said its majority-owned subsidiary, Citius Oncology, issued a press release on November 4, 2026, presenting health-related quality of life results from pivotal Study 302 of LYMPHIR in relapsed or refractory cutaneous T-cell lymphoma. The data were presented at the EORTC-CLTG 2026 Annual Meeting in Berlin, held October 8–10, 2026. The filing states the quality of life analyses were exploratory and descriptive, with no formal statistical comparisons, and it contains no financial results or guidance.
Responders (n=25) in the primary analysis set showed mean Skindex-29 Total Score changes from -5.38 to -13.69 points, where lower scores indicate better quality of life.
Responders' FACT-G Total Score change at end of treatment was +3.21, compared with -2.28 for non-responders.
Among 41 patients with a baseline itch score of 20 mm or greater, 13 (32%; 95% CI, 18.1–48.1) achieved a clinically meaningful itch improvement.
Citius Oncology is partnering with the Cutaneous Lymphoma Foundation on a Quality of Life Workshop scheduled for November 2026.
Emergent BioSolutions received a modification exercising an option period under an existing delivery order, valued at up to $22.3 million, to supply its BioThrax anthrax vaccine to the U.S. Department of War. The filing describes the award as an extension of an existing contract rather than a new financial result, and it does not report revenue, profit, or guidance changes.
Order valued at up to $22.3 million under an existing delivery order and IDIQ contract (W911SR24D0001)
First delivery valued at approximately $7.4 million, beginning this year, with remaining deliveries expected in 2027
Follows an August 2026 contract modification valued at approximately $24 million for CYFENDUS anthrax vaccine to BARDA
On November 4, 2026, Caliber (CaliberCos Inc.) said three more tokenized real estate offerings are live, with up to $85 million of combined offered equity. Investors in these offerings can choose a digital ownership token or a paper certificate, and the filing reports no financial results or guidance. The offerings are limited to accredited investors and are governed by their offering documents.
Three offerings are live: Caliber-Hyatt Studios Steamboat, Caliber-Hyatt Studios Phoenix/TSMC and the Caliber-HS Feeder Fund, with up to $85 million of combined offered equity.
Investors can receive a tokenized digital ownership certificate or keep the existing paper certificate.
With the earlier PURE Pickleball & Padel offering, the four live offerings represent more than $110 million of combined maximum offered equity, against an initial $100 million tokenization target.
Septerna, Inc. (Nasdaq: SEPN) said it selected SEP-204, an oral small molecule TSHR negative allosteric modulator, as a development candidate for Graves' disease and thyroid eye disease, and reported preclinical data ahead of a November 5, 2026 poster presentation at the American Thyroid Association meeting. The company plans to start a Phase 1 trial in healthy volunteers in the first quarter of 2027, but the filing reports no financial results or funding figures.
SEP-204 is designed for once-daily oral dosing, with a projected human half-life of approximately 20-40 hours.
Preclinical data showed selectivity of more than 1000-fold for TSHR over the related FSHR and LHR receptors.
In 28-day GLP toxicology studies in rats and dogs, SEP-204 was generally well tolerated.
Phase 1 trial initiation in healthy volunteers is planned for the first quarter of 2027.
Genprex announced that preclinical and supportive clinical research identifies TROP2 expression as a potential predictive biomarker of response to its lead drug candidate, REQORSA. The poster is scheduled for presentation at the 2026 EORTC-NCI-AACR Symposium in Barcelona, and the company says further research and prospective clinical evaluation are required before TROP2's predictive value is established.
Poster titled TROP2 Predicts Response to TUSC2 Gene Therapy is scheduled for Nov. 18, 2026 in Barcelona, Spain (Abstract 108, Board PB-108).
Approximately 50% of 10 NSCLC cell lines and 50% of 12 patient-derived organoid models showed primary resistance to TUSC2 gene delivery.
The filing states the findings are preclinical with supportive clinical evidence and that additional research is needed to establish predictive utility.
The filing contains no financial results, guidance, or financing terms.
D-Wave announced performance enhancements to its Stride hybrid solver, which it says found better solutions in 15 seconds than the previous version found in 120 seconds in key benchmark testing. The company also launched a three-course Applied Quantum Optimization learning path for developers. The filing contains no financial results, guidance, or deal terms, so the news is a product and training update with no stated direct financial effect on shareholders.
Enhanced Stride solver, now available in the Leap quantum cloud service, found better solutions in 15 seconds than the previous version found in 120 seconds in key benchmarks.
Traveling salesperson problems with up to 10,000 locations: solutions averaged within 0.02% of the best possible result in 15 seconds, more than 200x closer than the previous solver at the same runtime.
New three-course Applied Quantum Optimization learning path is available today through the Leap quantum cloud service.
Announced November 4, 2026 via Form 8-K Item 7.01 and Exhibit 99.1.
NeOnc Technologies Holdings announced that data from its intranasal NEO100 and oral NEO212 programs will be presented in two posters on November 13, 2026, at the 31st Annual Meeting of the Society for Neuro-Oncology in Philadelphia. The filing is an announcement of scheduled presentations and contains no financial results, guidance, or new financing terms.
Two poster presentations scheduled for Friday, November 13, 2026, 7:30 to 9:30 p.m. EST, at the Pennsylvania Convention Center in Philadelphia
NEO100 poster: updated Phase 1/2a results in recurrent WHO Grade III/IV IDH1-Mutant Astrocytoma, presented by Thomas C. Chen, MD, PhD
NEO212 poster: Phase 1 safety, pharmacokinetics and early activity signals in TMZ-Resistant recurrent GBM, presented by Josh Neman, PhD
Both NEO100 and NEO212 remain investigational and have not been approved by any regulatory authority
Profound Medical's U.S. subsidiary appointed Cook Medical as a non-exclusive distributor of the TULSA-PRO system in the United States, for use with Cook's intraoperative MRI equipment. The filing does not disclose financial terms, and the initial five-year term does not start until FDA clearance for use with Cook's equipment is provided, so the deal's effect on shareholders depends on that clearance and on sales volumes.
Agreement dated October 28, 2026, effective October 23, 2026; Cook is a non-exclusive U.S. distributor of TULSA-PRO for use with Cook's iMRI equipment.
The five-year initial term begins on the date Profound provides Cook with written evidence of FDA clearance; Cook may terminate without liability if that has not occurred by April 30, 2027.
Cook will buy TULSA-PRO systems at a predetermined transfer price, while Profound keeps single-use disposables and service contract revenue from customers who buy through Cook.
The filing does not disclose purchase volumes, transfer prices or other dollar figures.
Cenntro said it delivered 20 LS450 electric trucks in the United States under the New York Truck Voucher Incentive Program, generating more than $2.44 million in total revenue. The LS450 also qualified for California and New Jersey incentive programs, which the company says could broaden customer access to incentives.
20 LS450 electric trucks delivered under the New York Truck Voucher Incentive Program (NYTVIP)
More than $2.44 million in total revenue from these deliveries
Company plans LS450 deliveries under the New York City Clean Trucks Program (NYCCTP)
LS450 listed under California Clean Fuel Reward and New Jersey Zero-Emission Incentive Program
SurgePays said it signed a prepaid wireless purchase agreement on September 30, 2026 with Zulie Venture Inc. (dba Etime system), which committed to buy at least $48 million in prepaid wireless volume from October 1, 2026 through September 30, 2027. The company warned that the net revenue and gross profit it recognizes from this volume may be significantly lower than the stated volume, and that Etime system's commitment is not assured.
Etime system committed to a minimum of $4 million per month, with shortfalls to be made up by the end of the following month.
The agreement renews automatically for successive twelve-month terms unless either party gives notice at least thirty days before the term ends.
Transactions began in October 2026 and are processed through SurgePays POS.
The filing states that volume is not revenue and that net revenue and gross profit may be significantly lower.
UFP Industries said its Deckorators brand has expanded its distribution partnership with Wausau Supply Company, extending Deckorators decking and railing products across Wausau's full network of dealers in 42 states. The filing furnishes a press release and contains no financial results, guidance or dollar figures, so the effect on UFP's financial performance is not quantified.
Expansion announced November 2, 2026, building on a partnership established in February 2025 in seven states.
Wausau Supply operates more than 20 distribution centers serving dealers in 42 states and Canada.
Deckorators will be distributed through a three-partner network with ProWood and Forest Products Supply, which the company says reaches all 50 states.
XMax entered into a five-year GPU computing services agreement with DSH Hyper Pte. Ltd., which will supply dedicated capacity sourced from kt cloud in Korea, with service starting October 29, 2026. Total scheduled charges are about $122.5 million, but the long-term commitment depends on board approval and delivery of security by November 17, 2026, and the company's press release projects more than $100 million in cumulative revenue from related businesses over five years.
Initial configuration of 60 NVIDIA B300 nodes (480 GPUs) and 300 TB of storage, expanding to 64 nodes (512 GPUs) and 560 TB; expansion components become billable only after acceptance testing.
Total scheduled charges of about KRW 162.3 billion (about US$122.5 million) over a 60-month term ending October 28, 2031, excluding taxes.
First payment of about US$2.1 million is due November 6, 2026 as a non-refundable setup fee; if closing conditions are not met, it is the company's sole liability.
Company must provide a standby letter of credit of about US$8.2 million and a corporate guarantee to KT, subject to board approval and delivery by November 17, 2026.
Eton Pharmaceuticals announced ET-900, a new development program evaluating its mecasermin injection, the active ingredient in INCRELEX, for infantile and epileptic spasms, and said it licensed related patent rights from Baylor College of Medicine. A research Investigational New Drug application has been submitted to the FDA for an investigator-sponsored Phase 2 study, with initial enrollment and dosing targeted for the first quarter of 2027. The filing contains no financial figures, so its near-term financial effect is not quantified, and Eton retains commercial rights to ET-900 according to the press release.
Research IND submitted to the FDA for an investigator-sponsored Phase 2 study of mecasermin in children with refractory epileptic spasms
Study expected to enroll up to 20 patients ages 2–18 across three sites: University of Chicago, Baylor College of Medicine, and UCLA
Initial enrollment and patient dosing targeted for the first quarter of 2027
Preclinical animal data cited in the press release showed approximately 50% reduction in daily spasm counts
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.